Skip to main content

Table 1 Baseline values and outcomes for transferred and non-transferred patients

From: Inter-hospital transport of critically ill patients to manage the intensive care unit surge during the COVID-19 pandemic in France

  Transferred
n = 68
Non-transferred
n = 65
P value
Age, median (IQR), year 62 (55–70) 64 (54–71) 0.77
Male sex, no. (%) 47 (69) 48 (74) 0.54
BMI, median (IQR), kg/m2 29 (25–32) 29 (27–33) 0.27
SAPS II score at admissiona, median (IQR) 33 (25–46) 35 (27–42) 0.53
SOFA score at admissiona, median (IQR) 4 (3–6) 3 (2–5) 0.25
Onset of symptoms before ICU admission, median (IQR), days 9 (7–12) 10 (8–12) 0.34
Alcohol chronic intoxication, no. (%) 3 (3) 7 (11) 0.09
Cardiovascular comorbidities, no. (%) 36 (53) 34 (52) 0.94
Respiratory comorbidities, no. (%) 13 (19) 15 (23) 0.56
Renal comorbidities, no. (%) 5 (7) 7 (11) 0.56
Metabolic comorbidities, no. (%) 27 (38) 24 (37) 0.74
Malignant comorbidities, no. (%) 4 (6) 7 (11) 0.36
Chronic betablockers medication, no. (%) 15 (22) 9 (14) 0.22
Chronic ACE inhibitors medication, no. (%) 23 (35) 23 (34) 0.85
Chronic corticosteroids medication, no. (%) 3 (4) 3 (5) 0.99
Patients’ outcome and support at admission and over stay in Poitiers, Rennes, and Tours ICUs
 Proning, no. (%) 24 (35) 42 (65) 0.001
 Number of proning session(s), median (IQR) 2.5 (1.5–4) 3 (1–5) 0.43
 Implantation of veno-venous ECMO, no. (%) 5 (7) 7 (11) 0.49
 Length of veno-venous ECLS, median (IQR), days 18 (6–38) 9 (7–12) 0.52
 Vasopressors use, no. (%) 44 (65) 45 (69) 0.58
 Occurrence of AKI, no. (%) 18 (26) 29 (45) 0.03
 Need for RRT, no. (%) 8 (12) 9 (14) 0.79
 Occurrence of bacteremia, no. (%) 10 (15) 5 (8) 0.31
 Occurrence of thrombotic event, no. (%) 25 (37) 20 (31) 0.54
Primary and secondary outcomes
 ICU mortality, no. (%) 7 (10) 8 (12) 0.71
 Hospital mortality, no. (%) 8 (12) 8 (12) 0.92
 ICU-acquired infections, no. (%) 37 (54) 34 (52) 0.82
 Length of mechanical ventilation, median (IQR), days 18 (11–24) 14 (8–20) 0.007
 Length of intra-venous sedation, median (IQR), days 10 (6–17) 11 (6–18) 0.57
 Duration of neuromuscular blocking agents, median (IQR), days 2 (1–5) 5 (3–9) 0.008
 Length of vasopressor use, median (IQR), days 2.5 (2–5) 3 (2–5) 0.77
 ICU length of stay, median (IQR), days 22 (16–32) 19 (11–28) 0.07
 Hospital length of stay, median (IQR), days 36 (24–48) 30 (19–45) 0.11
  1. AKI acute kidney injury, BMI body mass index, ECMO extra-corporeal membrane oxygenation, ICU intensive care unit, IQR interquartile range, RRT renal replacement therapy, SAPS simplified acute physiology score, SOFA sequential organ failure assessment
  2. aScores calculated at initial admission in Rennes, Poitiers, and Tours for the non-transferred group and in Paris and East of France for the transferred group